Wells Fargo’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.78M Buy
83,071
+52,744
+174% +$3.81M ﹤0.01% 2555
2026
Q1
$2.07M Sell
30,327
-56,594
-65% -$4.01M ﹤0.01% 3238
2025
Q4
$6.6M Buy
86,921
+35,478
+69% +$2.58M ﹤0.01% 2405
2025
Q3
$3.16M Buy
51,443
+7,506
+17% +$391K ﹤0.01% 2969
2025
Q2
$2.15M Buy
43,937
+4,582
+12% +$218K ﹤0.01% 3171
2025
Q1
$2.01M Buy
39,355
+1,207
+3% +$60.2K ﹤0.01% 3155
2024
Q4
$1.72M Buy
38,148
+11,499
+43% +$492K ﹤0.01% 3309
2024
Q3
$989K Sell
26,649
-4,188
-14% -$140K ﹤0.01% 3553
2024
Q2
$943K Buy
30,837
+3,232
+12% +$105K ﹤0.01% 3533
2024
Q1
$803K Buy
27,605
+2,193
+9% +$61.4K ﹤0.01% 3590
2023
Q4
$700K Sell
25,412
-27,886
-52% -$638K ﹤0.01% 3644
2023
Q3
$1.19M Sell
53,298
-10,044
-16% -$374K ﹤0.01% 3202
2023
Q2
$2.58M Buy
63,342
+23,436
+59% +$1.15M ﹤0.01% 2699
2023
Q1
$1.93M Buy
39,906
+38,763
+3,391% +$1.77M ﹤0.01% 2896
2022
Q4
$43.6K Sell
1,143
-1,867
-62% -$77.6K ﹤0.01% 4920
2022
Q3
$151K Sell
3,010
-815
-21% -$39.9K ﹤0.01% 4390
2022
Q2
$154K Sell
3,825
-34,236
-90% -$1.2M ﹤0.01% 4418
2022
Q1
$1.42M Sell
38,061
-22,544
-37% -$869K ﹤0.01% 3595
2021
Q4
$2.41M Buy
60,605
+2,994
+5% +$115K ﹤0.01% 3302
2021
Q3
$2.14M Buy
57,611
+11,869
+26% +$488K ﹤0.01% 3611
2021
Q2
$1.93M Sell
45,742
-22,439
-33% -$961K ﹤0.01% 3723
2021
Q1
$3.23M Sell
68,181
-16,579
-20% -$985K ﹤0.01% 3268
2020
Q4
$5.17M Buy
84,760
+18,633
+28% +$1.1M ﹤0.01% 2721
2020
Q3
$3.09M Sell
66,127
-102,531
-61% -$5.05M ﹤0.01% 2963
2020
Q2
$8.56M Buy
168,658
+45,750
+37% +$2.25M ﹤0.01% 1990
2020
Q1
$5.48M Buy
122,908
+85,264
+227% +$4.29M ﹤0.01% 2160
2019
Q4
$1.81M Sell
37,644
-67
-0.2% -$2.85K ﹤0.01% 3423
2019
Q3
$1.27M Buy
37,711
+3,770
+11% +$164K ﹤0.01% 3659
2019
Q2
$1.53M Sell
33,941
-55,414
-62% -$2.19M ﹤0.01% 3557
2019
Q1
$3.36M Buy
89,355
+1,356
+2% +$45.5K ﹤0.01% 2923
2018
Q4
$3.02M Buy
87,999
+52,250
+146% +$1.88M ﹤0.01% 2927
2018
Q3
$1.68M Sell
35,749
-95,082
-73% -$3.93M ﹤0.01% 3550
2018
Q2
$4.41M Buy
130,831
+51,475
+65% +$1.61M ﹤0.01% 2809
2018
Q1
$2.15M Buy
79,356
+3,199
+4% +$81.1K ﹤0.01% 3326
2017
Q4
$1.27M Buy
76,157
+23,164
+44% +$392K ﹤0.01% 3757
2017
Q3
$1.06M Sell
52,993
-732
-1% -$14.3K ﹤0.01% 3810
2017
Q2
$985K Sell
53,725
-9,721
-15% -$131K ﹤0.01% 3744
2017
Q1
$625K Sell
63,446
-8,209
-11% -$99.4K ﹤0.01% 4096
2016
Q4
$782K Buy
71,655
+33,477
+88% +$351K ﹤0.01% 3886
2016
Q3
$535K Buy
38,178
+8,491
+29% +$69K ﹤0.01% 3918
2016
Q2
$209K Sell
29,687
-1,880
-6% -$13.8K ﹤0.01% 4383
2016
Q1
$202K Sell
31,567
-1,435,331
-98% -$24.9M ﹤0.01% 4408
2015
Q4
$47.5M Sell
1,466,898
-443,633
-23% -$13.1M 0.02% 792
2015
Q3
$51M Buy
1,910,531
+317,171
+20% +$13.6M 0.02% 736
2015
Q2
$76.7M Buy
1,593,360
+595,852
+60% +$34.8M 0.03% 619
2015
Q1
$60.7M Buy
997,508
+644,893
+183% +$39.3M 0.02% 696
2014
Q4
$18.3M Buy
352,615
+311,067
+749% +$13.7M 0.01% 1346
2014
Q3
$1.83M Buy
41,548
+37,992
+1,068% +$1.19M ﹤0.01% 3057
2014
Q2
$92K Buy
3,556
+317
+10% +$6.79K ﹤0.01% 4717
2014
Q1
$84K Buy
3,239
+239
+8% +$6.42K ﹤0.01% 4730
2013
Q4
$51K Sell
3,000
-25,733
-90% -$452K ﹤0.01% 4742
2013
Q3
$617K Buy
+28,733
New +$499K ﹤0.01% 3642

Other funds holding PTCT

Wells Fargo's PTCT Position: Q2 2026 in Review

Wells Fargo increased its PTC Therapeutics (PTCT) stake by 174% in Q2 2026, buying an estimated $3.81M and bringing the position to 83,071 shares worth $6.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2555.

Wells Fargo first reported a position in PTCT in Q3 2013 and has held it in 52 quarters since. The position peaked at $76.7M in Q2 2015. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Wells Fargo held 83,071 shares of PTC Therapeutics worth $6.78M as of Q2 2026.
  • Wells Fargo bought 52,744 PTC Therapeutics shares in Q2 2026, an estimated $3.81M.
  • PTC Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2555 holding.
  • Wells Fargo first reported a position in PTC Therapeutics in Q3 2013 and has held it in 52 quarters since.
  • Wells Fargo's PTC Therapeutics position peaked at $76.7M in Q2 2015.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.